GOVERNMENT OF INDIA MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH)

LOK SABHA UNSTARRED QUESTION NO. 1014 TO BE ANSWERED ON 18th SEPTEMBER, 2020

AYURVEDIC DRUGS AND PROTOCOL FOR COVID-19

1014. SHRI SUDHAKAR TUKARAM SHRANGARE: SHRI SUNIL KUMAR SINGH: PROF.SAUGATA RAY: SHRI SUMEDHANAND SARASWATI:

Will the Minister of AYURVEDA, YOGA AND NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

- (a) whether any proposal on Ayurvedic Drug and Protocol developed for Covid 19 by a team of eminent Ayurvedic physicians for clinical trials is under consideration of the Government;
- (b) if so, the details thereof alongwith the reasons for inordinate delay in granting permission for clinical trials; and
- (c) the remedial steps taken by the Government in this regard?

ANSWER THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. HARSH VARDHAN)

(a)& (b): Ministry of AYUSH has formed an Inter-disciplinary AYUSH R&D Task Force. Task Force has formulated and designed clinical research protocols for prophylactic studies and add-on interventions in COVID-19 positive cases through thorough review and consultative process of experts of high repute from different organizations across the country for studying four different interventions viz. Ashwagandha, Yashtimadhu, Guduchi + Pippali and a poly herbal formulation (AYUSH-64). Ayush Sanjivani mobile app developed by Ministry of AYUSH has also been launched to generate data on acceptance and usage of AYUSH advocacies and measures among the population and its impact in prevention of COVID-19 targeting 05 million population. All these studies are at various stages of conduction.

Further, a total of 247 proposals of Ayurveda interventions have been received under modified Extra Mural research (EMR) Scheme for SARS CoV-2 infection and COVID-19 disease. Out of 247 proposals, 21 research proposals recommended by competent authority on Ayurveda for SARS/COVID cases have been approved for funding.

(c): In view of (a) & (b) above, the question does not arise.